A well designed clinical trial requires an appropriate sample size with adequate statistical power to address trial objectives. The statistical power is traditionally defined as the probability of rejecting the null hypothesis with a pre-specified true clinical treatment effect. This power is a conditional probability conditioned on the true but actually unknown effect. In practice, however, this true effect is never a fixed value. Thus we discuss a newly proposed alternative to this conventional statistical power: statistical assurance, defined as the unconditional probability of rejecting the null hypothesis. This kind of assurance can then be obtained as an expected power where the expectation is based on the prior probability distribution of the unknown treatment effect, which leads to the Bayesian paradigm. In this paper, we outline the transition from conventional statistical power to the newly developed assurance and discuss the computations of assurance using Monte-Carlo simulation-based approach.
Introduction
Clinical trials should be well designed for ethical consideration as well as cost
effectiveness. An aspect of good design of clinical trial protocol is to determine appropriate number of patients (i.e., sample size) with adequate statistical power to address the clinical objectives. The statistical power is traditionally defined as the probability of rejecting the null if the true clinical trial treatment effect equals a prerequisite value. Therefore the statistical power is a conditional probability to this unknown prerequisite value, as discussed extensively in Chow et al. (2003) , Chen and Peace (2011) , and Walter and Chen (2014) . In practice, this prerequisite value is obtained from previous trials or specified based on prior experience and knowledge, which could very well be different from the true treatment effect and then could lead to an imprecise statistical power and its associated sample size.
As a result, the traditional statistical power used to "power" a clinical trial cannot actually assure a successful clinical trial. To assure a successful clinical trial, a newly proposed alternative to this conventional statistical power is "assurance" which is defined as the unconditional probability of rejecting the null hypothesis as propagated in O' Hagan and Stevens (2001) , O'Hagan et al. (2005) , Chuang-Stein (2006) , Chow and Chang (2012) , and Ren and Oakley (2012) . This assurance can then be obtained as the expected power with respect to the prior probability distribution of the prerequisite value, which leads to the Bayesian paradigm. O'Hagan et al. (2005) discussed the computational aspects with WinBUGS and gave the analytical formula 3 | P a g e for normally distributed data when the variance is known and the Bayesian clinical trial simulation (BCTS) when the variance is unknown. They also discussed how to apply BCTS to binary data. Chuang-Stein (2006) also illustrated the calculations for normal data with known variance using SAS/R by numerical integration. For time-to-event data, Ren and Oakley (2014) reviewed various methods and the associated calculations.
Assurance, as an alternative to the important concept of statistical power, is still new to many biostatisticians, clinicians and government regulators. Further illustrations of this concept along with software implementation for public use remain an unmet practical need, which leads to this paper. In this paper, we outline the concept of assurance and discuss the computations of assurance using Monte-Carlo simulation-based approach.
In Section 2, we outline the concept of transitioning from the conventional statistical power to assurance. In Section 3, we demonstrate the implementation of Monte-Carlo simulation-based approach to calculate statistical power and assurance. Finally, in Section 4, a discussion is provided.
Conventional Statistical Power to Assurance

Conventional statistical power and its limitations
Typically, the general objective of a clinical trial is to compare whether a new drug is better than placebo. In order to demonstrate the new drug is effective, one needs to determine how many patients should be enrolled in each treatment. In statistical terms, the null hypothesis H0 is defined as the two treatments being not different versus the alternative hypothesis Ha is defined as the new drug being better than placebo. The hypothesis testing is then to test whether there is a statistically significant treatment effect between these two treatments. The associated concepts for this hypothesis testing are the type-I error and type-II error. The type-I error (α, typically controlled at 4 | P a g e 5%) is defined as the probability of rejecting the null hypothesis when it is true and the type-II error (β) as the probability of not rejecting the null hypothesis when it is false. The statistical power (π) is then defined as the probability of rejecting the null hypothesis when it is false (i.e., π = 1 − β), which is typically set between 0.8 and 0.9. The associated sample size can then be determined based on this power and the type-I error rate. 
where π(. ) is the power function and θ is a vector of the assumed parameters, such as the treatment effect, sampling variance and possible others. It can be seen that the statistical power defined in equation (1) is a conditional probability of R conditioned on the unknown parameter vector θ. The value of this power as well as the associated sample size calculation is then dependent on the unknown parameter vector θ.
Generally, this parameter vector θ cannot be provided precisely in practical clinical trials as pointed out in O'Hagan et al. (2005) and others. Therefore the statistical power, as one of the most important concepts in clinical trials, traditionally has been quoted as a fixed probability based on a prerequisite parameter value from the unknown alternative hypothesis parameter space. It is rare that the observed data will coincide with the prerequisite parameter value, which often lead to the issue of over-powering or under-powering a clinical trial.
Assurance in clinical trials
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To eliminate these limitations from the conventional statistical power, O'Hagan and Stevens (2001) advocated the "assurance" (denoted by ) as an alternative to this statistical power, which is defined as an unconditional probability to reject the null hypothesis, i.e. = ( ), where R is rejection of the null hypothesis. The assurance can then be viewed as the expected power to the parameter vector space of . It can be seen that
where the expectation is to the (prior) probability distribution of parameter vector space of θ.
With this definition, the "assurance" provides a bridge between the frequentists' approach in statistical power and the Bayesian paradigm of averaging or integrating out the conditional statistical power with all possible (prior) values of parameter vector space of θ. This assurance can then provide an unconditional probability or evidence to assess the success of a clinical trial and therefore is more realistic and robust than that of the conventional statistical power.
As pointed out in O'Hagan et al. (2005) , the concept of assurance can be dated back to the 1980s by Spiegelhalter and Freedman (1986) and later named as a 'hybrid classical-Bayesian' approach in Spiegelhalter et al. (2004) . To our experience and knowledge in clinical trials, it is very reasonable to use this hybrid frequentist-Bayesian approach in study design since prior information has always been used to calculate sample size. Whenever this prior information for the unknown parameter θ (i. e., treatment effect) is sufficiently strong such that the prior variance would approach to zero, the assurance defined in equation (2) would approach the conventional statistical power defined in equation (1). On the other hand, if the prior information is weak, the prior variance would be large and the assurance defined in equation (1), which averages all the potential values of this vague prior distribution, would be more appropriate than the conventional statistical power to assess the probability of a successful trial.
Illustrations
Conceptually, assurance defined in equation (2) is the expected power to the parameter vector space of . Depending on the dimension of this parameter vector space, the expected power can be high-dimensional integration, which makes analytical formula virtually impossible. As an illustration from the computational aspect, we use the simple case of normally distributed data for two treatments to illustrate the transition process from statistical power to assurance.
Suppose that in a two-treatment clinical trial with ni patients randomized to treatment i (i = 1, 2), the continuous outcome xij from jth patient is normally distributed as ~( , 
This analytical formulation can reconcile the numerical integration proposed in Chuang-Stein (2006) where the assurance is defined as the probability to produce a successful trial. This paper elegantly conceptualizes the assurance from the biopharmaceutical aspects and illustrates the calculations from the designing aspect of a clinical trial. It defines the "success" as a "Trial produces a significant p-value". With this definition, the assurance is given by the equation (2) in Chuang-Stein (2006) as follows:
where (Trial produces a significant p-value|Δ) in equation (4) The assurance given in equation (4) can be obtained only through a numerical integration and a trapezoid role was used in Chuang-Stein (2006), which was coded in both R and SAS in the appendix.
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It can be shown that Chuang-Stein's definition in equation (4) Table 1 in Chuang-Stein (2006) to illustrate the conventional statistical power and assurance calculation when there are 128 and 172 patients per group with prior distribution of (2.5, (2/ )7.14 2 ) with the prior sample size m = 25 and 70.
It can be seen from Appendix 1 that O'Hagan et al. (2005)'s formulation can be easily implemented using the standard normal cumulative distribution while the Chuang-Stein's formulation will need to call the numerical integration routine in R (i.e. "integrate") to obtain the integration in equation (4). We reproduced the results in Table 1 Table 1 .
9 | P a g e To further illustrate the conventional statistical power and assurance under different sample sizes, we provide Figure 1 and its range of sample sizes for clincical trials. It can be seen and expected that the assurance is typically smaller than the conventional statistical power when sample sizes are larger (> 60 in this figure where statistical power > 0.5) because the assurance is intergrated over all possible parameter vector values. However, it is interesting to observe that when the sample sizes are relatively small and the clinical trials would be underpowered (<=50%), the assurance and the conventionoal statistical power are similar.
10 | P a g e Table 1 where the statistical powers are 0.8 and 0.9, and assurances are 0.633 and 0.677, respectively.
Assurance Calculations
The illustration in Section 2.3 can only be done using some simple cases with one-dimensional parameter vector . Conceptually, assurance defined in equation (2) is the expected power to the parameter vector space of which could be high-dimensional. When the expected power involves high-dimensional integration, it will be impractical to obtain the analytical formula to be implemented in statistical software. With the computing technology, we can resolve the assurance 11 | P a g e computations by Monte-Carlo simulation-based approach. Simulation-based computations for designing and analyzing clinical trials have been seen in Kimko and Duffull (2002) , Kimko and Peck (2010) , and Chow and Chang (2012) . Here our focus is for assurance computations. We describe the Monte-Carlo simulation-based computations in this section by using R (in Appendix 2).
Bayesian Clinical Trial Simulation (BCTS) to Monte-Carlo Simulation-Based (MCSB) approach
As proposed in O'Hagan et al. (2005) for assurance calculation, the general principle for BCTS is to incorporate sampling from the prior distribution of before sampling from the data.
Specifically, the general algorithm to compute the assurances of outcomes A1, A2, …, Ak, is as follows: In fact, this BCTS can be simplified with the following MCSB approach (hereafter referred as MCSB-General) for computing assurance that involves the following steps:
1. Define counter I for iteration and the required number of simulations, N, (say N = 1,000,000 simulations). Set I = 0 and start looping; 2. Sample from the joint prior distributions, 3. Calculate the conventional statistical power conditional on this sampled value of from step 2 with the data or calculated test statistics using the associated model for hypothesis testing, 4. The assurance can be estimated as the average of the statistical powers from step 3
We illustrate this BCTS-General to normally distributed data and binary data in the following sections.
Assurance calculation for normally distributed data when variance is unknown
When the variances are unknown, the commonly used test statistic is the Student t. Under the homogeneous variance assumption, this test statistic is formulated as = This MCSB-Normal approach is implemented in R as seen in Appendix 2. We first implemented this MCSB-Normal in Appendix 2.1 with known variance (i.e., the function "ANDks" in short for "Assurance for Normal Data with Known Sigma") to confirm the results given by Chuang-Stein (2006) shown in the middle column of Table 1 . We then programed the MCSBNormal with unknown variance in Appendix 2.2 (i.e., ANDus in short for "Assurance for Normal
Data with unknown sigma") for the same scenarios and the estimated assurances from this MCSBNormal shown in the right column in Table 1 . It can be seen from these results that the assurances with unknown variance are smaller than the assurances with known variance. This is considered reasonable and consistent with general conclusion in the statistical power. When the variance is known, then the calculations can be done more precisely, whereas when the variance is unknown, it needs to be estimated and therefore introduces additional variability in assurance calculations.
Assurance calculation for binary data with O'Hagan et al. (2005)'s formulation
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In clinical trials with binary data with xi successes from total ni patients for treatment i (i = 1, 2), denote as the population success rate for treatment i. 
where Փ(.) is the standard normal density function.
This definition of statistical power is a conditional probability conditional on two unknown parameters 1 and 2 from both treatments. The assurance would then be calculated by integrating these two unknown parameters 1 and 2 from their joint prior distributions, which are typically beta conjugate prior distributions. This would not be feasible to obtain analytical formula based on the equation (5). However, this can be easily implemented with MCSB approach (hereafter referred as MCSB-Binary) as follows:
1. Set counter I = 0 and the number of simulations N (say, N=1,000,000), 2. Sample 1 and 2 from their prior distributions which are typically beta-distributions, 3. Calculate the Z-statistic and then the statistical power using equation (5), 4. Estimate the assurance with the average of the resulted sample of N statistical powers.
This MCSB-Binary approach is implemented in R as seen in Appendix 2.3. We make use of example 4 in Section 5.1 from O'Hagan et al. (2005) for clinical trials in rheumatoid arthritis where prior information for control drug is specified as E(p1) = 0.2 and sd(p1) = 0.08 from the published results for methotrexate in Kremer et al. (2002) . This prior information can be represented by a beta-distribution as p1 ~ Beta(5, 20). The new drug has more uncertainty as specified by E(p2) = 0.4 and sd(p2) = 0.17, which corresponds to beta-distribution as p2 ~ Beta(3, 4.5).
Recognizing the ineffectiveness, the development team used a weighting scheme with a 0.15 probability for Beta (2, 23) and 0.85 for Beta (3, 4.5). The trial was planned with unequal sample size, n1= 200 patients in the control (methotrexate) group and n2 = 400 in the treatment group for a two-sided 5% significance level test for superiority. With these sample sizes to detect an improvement from p1= 0.2 to p2 = 0.3 (i.e. a 50% treatment effect), the statistical power can be calculated by equation (5) to be 78%. Using the MCSB-Binary described above, which is implemented in Appendix 2.3, the assurance is 0.633, smaller than the conventional power of 0.78.
Assurance calculation for binary data with logit-normal formulation
In designing and analyzing binary data, it is common to consider the logit-normal transformation to the response rates which then lead to the logistic regression for categorical data. The logitnormal formulation was introduced in Mead (1965) and Aitchison and Shen (1980) . In analyzing dose-response relationship incorporating historical control data, Chen (2010) used this logitnormal formulation with an empirical Bayes approach.
Traditionally, this transformation is as follows: ( ) = ( 1− ) = for each treatment i=1 and 2. It is known that the ratio pi/(1-pi) is the odds of success so that logit(pi) is often called the log odds, which is used as logit link in generalized linear model for binary or 16 | P a g e binomial data (see, for example, Chen and Peace, 2011) . Transforming this back, we would have
; therefore, the typical null hypothesis H0: p1 = p2 is equivalent to H0: 1 = 2 .
With this logit-normal transformation to pi, the αi is usually assumed to be normally distributed
and then the MCSB approach can be implemented to sample the from the above distribution in equation (6).
The MCBS approach (hereafter referred as MCSB-Power) to estimate the statistical power for testing treatment efficacy between two treatments with sample sizes n1, n2 and probabilities 1 and 2 , can be implemented by the following steps:
1. Set counter I = 0 and the number of simulations, N (say, N=1,000,000), 2. Sample ~( , ) and perform logistic regression to test the null hypothesis H0: 1 = 2 , or essentially H0: p1 = p2, 3. If the associated p-value from this logistic regression is less than 0.05 for H0, increase I by one, 4. Repeat steps 2 and 3 for N times and the statistical power can be then estimated by I/N. Now this MCSB approach can be similarly implemented to calculate the assurance using the logit-normal formulation (hereafter referred as "MCSB-LogitNormal") for testing treatment efficacy between two treatments with sample sizes ni, probabilities and 2 (i=1,2), can be implemented by the following steps:
1. Set counter I = 0 and the number of simulations, N (say, N=1,000,000), 2. Sample ~( ( 1− ) , 2 ) from equation (6) Both MCSB-Power and MCSB-LogitNormal proposed above can be easily implemented in any software that handles logistic regression. Appendix 3 is the R code for these two approaches.
To illustrate these approaches, again we make use of the Section 5.1 in O'Hagan et al.
(2005) for clinical trials in rheumatoid arthritis where p1= 0.2 and p2 = 0.3, which corresponds to 1 = −1.386 and 2 = -0.847 respectively. To simplify the illustration and without loss of generality, we assume 1 2 = 2 2 = 2 and consider one case of small variance 0.01 and the other case of large variance 0.1. In addition, we consider equal sample size for the two treatments (i.e. n = n1 = n2). With these settings, we run these two MCSB approaches for sample sizes from 50 to 800 and calculate the statistical power using MCSB-Power and assurance using MCSBLogitNormal. The results are summarized in Table 2 and graphically displayed in Figure 2 . Table 2 . "MCSB-Power" approach for statistical power (the 2 nd column) and "MCSBLogitNormal" approach for assurance with variance =0.01(the 3 rd column) and assurance with variance =0.1 (the 4 th column) for various sample sizes (1 st column). It can be seen from Table 2 and Figure 2 that the statistical power is generally larger than the assurance for sufficient large sample size (>180 in this simulation) but similar for small sample size (< 180 in this simulation). This conclusion is consistent with the results in Table 1 and Figure   1 . It is observed that the statistical power is greater than 0.8 for sample size 300 per group. This power is similar to the result in Section 3.3 where it is 0.78 for sample size of 200 for the control group and 400 for the treatment group. It is also observed that given this sample of 300, the assurance (expected probability to have a successful trial) is 0.76 and 0.67 for variance = 0.01 and variance = 0.1, respectively, which are smaller but not by much. In order to have assurance to be 0.8 to ensure an absolute successful trial, the sample size would have to be 350 (where the power is 0.85) for smaller prior variance (i.e., when variance =0.01) and an enormous 800 (where the power is 0.99) for large prior variance (i.e., when variance =0.1), as seen in Table 2 and Figure 2 .
With a further increase the sample size from 300 to 400, the associated statistical power increases from 0.8 to 0.9, roughly a 12% increase. Nonetheless, the assurance increase is about 10% from 0.76 to 0.84 for smaller variance of 0.01 and 6% from 0.66 to 0.70 for large variance of 0.1. It is important to observe that the assurance is bounded. In our case with the larger variance of 0.1, the assurance limit is roughly 0.7, no matter how big the sample size is. This indicates that assurance is constrained by the variability of prior information, which is reasonable because with uncertainty in the prior distribution and without collecting the actual data, it is impossible to be 100% assured that a trial will be successful. In light of this, assurance should be compared within the context, rather than in a vacuum or using the absolute magnitude.
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Discussion
In this paper we illustrated the transition from the conventional statistical power to assurance proposed in O'Hagan and Stevens (2001) in designing clinical trials. The conventional statistical power is the probability of rejecting the null hypothesis conditional on the specified treatment effect, whereas the assurance is the unconditional probability of a successful clinical trial averaged over the parameter space of this pre-specified treatment effect. Then the calculation of the assurance involved a high-dimensional integration would have to resort to numerical integration.
We promote the Monte-Carlo simulation-based approach in this paper and illustrated its implementation in R for clinical trials with normally distributed data given known or unknown variances, as well as clinical trials with binary data from beta and logit-normal distributions.
It is common knowledge that a traditionally powered clinical trial at 80% to 90% does not guarantee 80% to 90% of probability of success, as the power calculation is based upon a prespecified fixed treatment effect which most likely will be different from the true treatment effect.
Typically the assurance is lower than the statistical power for a sufficient sample size, even though we observe that the assurance could be higher than the statistical power for underpowered clinical trials as seen in Figures 1 and 2 . It is well known that as the sample size increases and approaches to infinity, the traditional statistical power will approach to 1. However, the assurance will be bounded by a value less than 1 even when the sample size approaches to infinity. This can be analytically illustrated using the descriptions in Section 2.3. As study sample sizes (e.g., n1 and n2
in our examples) approach to infinity, the standard error (i.e., ) should approach to zero. The assurance defined in O'Hagan et al. (2005) would then approach to: = Φ ( √ ), which is the prior probability of success (positive outcomes).
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In the real world of clinical trials, we believe that the assurance can provide a more realistic and robust measure of probability of success than the traditional power can. Assurance does depend on the prior distribution of treatment effects, which can be very subjective with varying Bayesian priors. Thus the related issues in the Bayesian approach also apply to assurance.
Nevertheless, assurance typically will be used by the pharmaceutical industry sponsors for internal decision-making and therefore it is the industry sponsor's risk of using it. As such, it will also be at the industry sponsor's best interest to get the most relevant prior distribution for the treatment effect. This can be accomplished by various ways such as historical data driven or expert elicitation or a hybrid of both. Good decision-making is important for clinical development and therefore any method that can enhance good decision-making will be beneficial to patients, sponsors and regulators, as well as society in general.
[ dd=data.frame(x=c(xA,xB),trt=c(rep("A",n1),rep("B",n2))) md=glm(x~trt,dd,family="binomial");
pval.md = summary(md)$coef["trtB","Pr(>|z|)"] pow = pow+sum(pval.md < alpha) ### assurance simulation for sigma1 alphaA=rnorm(1,log(pA/(1-pA)),sqrt(sig2A)); alphaB=rnorm(1,log(pB/(1-pB)),sqrt(sig2B)) pAs = exp(alphaA)/(1+exp(alphaA));pBs = exp(alphaB)/(1+exp(alphaB)); xA = rbinom(n1,1,pAs);xB = rbinom(n2,1,pBs) dd = data.frame(x = c(xA, xB), trt = c(rep("A", n1), rep("B", n2))) md = glm(x~trt, dd, family="binomial");
30 | P a g e pval.md = summary(md)$coef["trtB","Pr(>|z|)"] assu1 = assu1+sum(pval.md < alpha) ### assurance simulation for sigma2 alphaA=rnorm(1,log(pA/(1-pA)),sqrt(sig2A2)); alphaB=rnorm(1,log(pB/(1-pB)),sqrt(sig2B2)) pAs = exp(alphaA)/(1+exp(alphaA));pBs = exp(alphaB)/(1+exp(alphaB)); xA = rbinom(n1,1,pAs);xB = rbinom(n2,1,pBs) dd = data.frame(x = c(xA, xB), trt = c(rep("A", n1), rep("B", n2))) md = glm(x~trt, dd, family="binomial");
pval.md = summary(md)$coef["trtB","Pr(>|z|)"] assu2 = assu2+sum(pval.md < alpha)
} #End of i-loop # output list(pow = pow/nsimu,assu1=assu1/nsimu,assu2=assu2/nsimu ) } # end of pow2assurance
